Venture capitalists, led by Ysios Capital and Forbion Growth, have assembled $80 million for NorthSea Therapeutics BV, enabling the Netherlands-based company to progress its lead product for non-alcoholic steatohepatitus (NASH) into Phase 3. The Series C financing was also supported by Novo Seeds and Sofinnova, among others.
